French biotech life sciences park welcomes 22 member

Biocitech, the Paris, France-based life science technology park, has announced that Pherecydes Pharma is the latest company to join the 21 other resident companies on its campus. This means the park's occupancy rate is now 93%.

Pherecydes is a biosecurity and biodefense company. It is developing biopharmaceutical solutions to threats from bacteria, as well as therapeutic and identification tools based on phage technology. The company offers biosensors for the real time identification of bacteria and solutions for surface decontamination. The company, whose chief executive is Thierry Raynaud, is a spin-off from the research activities of Bio-Modeling Systems SAS, a predictive integrative biology specialist.

"Anti-infectious research has always been part of the culture and history of the Biocitech site," said Biocitech's CEO, Jacques Lhomel. "We are really pleased to welcome Pherecydes Pharma as its activities are complementary to and will strengthen the anti-infectious research network already present at Biocitech. Its arrival will be a source of new inter-company synergies, one of the key concepts driving the development of the park," he added.